LEISHDNAVAX
Development of a DNA vaccine for visceral leishmaniasis
| Coordinatore | LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
Organization address
address: KEPPEL STREET contact info |
| Nazionalità Coordinatore | United Kingdom [UK] |
| Totale costo | 4˙096˙654 € |
| EC contributo | 2˙989˙200 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2007-B |
| Funding Scheme | CP-SICA |
| Anno di inizio | 2009 |
| Periodo (anno-mese-giorno) | 2009-01-01 - 2012-06-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE
Organization address
address: KEPPEL STREET contact info |
UK (LONDON) | coordinator | 556˙420.00 |
| 2 |
MOLOGEN AG
Organization address
address: Fabeckstrasse 30 contact info |
DE (BERLIN) | participant | 1˙198˙880.00 |
| 3 |
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Organization address
address: Chariteplatz 1 contact info |
DE (BERLIN) | participant | 260˙100.00 |
| 4 |
INSTITUT PASTEUR DE TUNIS
Organization address
address: Place Pasteur 13 contact info |
TN (TUNIS) | participant | 260˙100.00 |
| 5 |
DRUGS FOR NEGLECTED DISEASES INITIATIVE FONDATION*DNDI
Organization address
address: CHEMIN LOUIS DUNANT 15 contact info |
CH (GENEVE) | participant | 253˙800.00 |
| 6 |
THE HEBREW UNIVERSITY OF JERUSALEM.
Organization address
address: GIVAT RAM CAMPUS contact info |
IL (JERUSALEM) | participant | 230˙400.00 |
| 7 |
COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH
Organization address
address: Anusandhan Bhawan, Rafi Marg 2 contact info |
IN (NEW DEHLI) | participant | 130˙500.00 |
| 8 |
Indian Council of Medical Research
Organization address
address: Ansari Nagar contact info |
IN (New Delhi) | participant | 99˙000.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'This project will focus on the preclinical development of a DNA vaccine for human visceral leishmaniasis. The project is based upon the DNA vaccine technology and immunomodulators developed at Mologen AG (Berlin, Germany), which are in clinical development for cancer and 3-5 known antigens that already have demonstrated profiles of protection in animal models of leishmaniasis. Antigens will be selected on the basis of preset criteria to assure protection in high proportion of target populations and against many different species of Leishmania. In vitro and in vivo models will be used to evaluate the prophylactic and therapeutic efficacy of the DNA vehicle with selected antigens alone and in combination with and without immunomodulator. Full toxicology studies will be performed on selected candidate vaccines. Training in preclinical development and clinical trials (ICH-GCP) are an important part of the proposal. Sites will be selected and ready to initiate clinical trials at the end of this project (3 years).'